Unlocking the full therapeutic potential of psychedelics
A new type of biotech company
Credentialed science with viable commercial applications
Meeting the challenges of mainstreaming a new class of medicines
2013 - 2016
Assessment of Drug Class Clinical Feasibility and Translational Challenges
Founded in 2013, Eleusis is the first clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics through conventional clinical development and regulatory approval.
In 2015 and 2016, Eleusis conducted two clinical trials of lysergic acid diethylamide (LSD). These trials focused on establishing a basic framework for the future clinical development of psychedelics in the context of Alzheimer’s disease and depression.
Phase I Trials:
Low Dose LSD
Moderate Dose LSD
2017 - 2020
Development of Translational Solutions
Eleusis identified translational challenges to the clinical development of psychedelics in the context of psychiatry and as anti-inflammatory medicines. In psychiatric application, these challenges included the incidence of adverse effects (i.e. anxiety, nausea), prolonged treatment duration, and the intrapatient variability of dose response. Beyond Psychiatry, the primary challenge identified was to minimize the perceptual effects of psychedelics while maximizing the immunomodulatory and neuroprotective activity.
2020 - 2025
Clinical Development and New Drug Development
Eleusis is now embarking on a full clinical development program of ELE-Psilo as a treatment for major depressive disorder. In parallel, Eleusis is continuing its drug discovery and development programs beyond psychiatry in an effort to fully unlock the therapeutic potential of psychedelics.